2001
DOI: 10.1016/s0959-8049(01)81201-6
|View full text |Cite
|
Sign up to set email alerts
|

Gemcitabine, epirubicin and paclitaxel (GET) vs. 5-fluorouracil, epirubicin and cyclophosphamide (FEC) as first-line treatment in metastatic breast cancer: interim toxicity analysis of a randomised, multicenter phase iii trial of the Central European Cooperative Oncology Group (CECOG)

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
references
References 0 publications
0
0
0
Order By: Relevance